Japan’s anti-flu drug: Avigan very promising as COVID-19 drug: PHL FDA chief

Up until now, no known vaccine has been developed that will make cure as against the novel coronavirus 2019 disease or COVID-19.

Advanced countries are racing against time to find a cure as currently more than half million has been infected with the disease that came from Wuhan, China.

On March 28, Japan Prime Minister Shinzo Abe in a press conference anti-drug Avigan has attracted attention from many countries. Abe said that clinical trial process required for formal approval of the drug as treatment for the novel coronavirus 2019 will be launched.

Japan Prime Minister Shinzo Abe

The Prime Minister said Japan wouls be willing to work with other countries to expand clinical research and start increasing drug production.

“Very promising po siya, mukha po talaga siyang sa ngayon sa mga anti-viral ay ito po ang parang medyo directed po ang treatment towards talagang [sa] COVID-19,” Food and Drug Administration (FDA) director general Health Undersecretary Eric Domingo said in an interview with Dobol B sa News TV.

“Of course… this is a very early development drug, at nakita po na meron siyang positive response sa mga pasyente sa kanya,” he explained. “Kasi nga dinedevelop pa, wala pa po siyang production in commercial quantity pero tinitingnan din po natin kung pano siya maipapasok sa Pilipinas.”

Avigan is the brand name for anti-flu drug favipiravir. It s one of the drugs being tested worldwide as treatment for COVID-19, the other one is chloroquine, which is originally made to treat malaria.

What can you say about this?

Share us your thoughts by simply leaving on the comment section below. For more news updates, feel free to visit our site often.

Stay updated with today's relevant news and trends by hitting the LIKE button.

Thanks for dropping by and reading this post.

Report from mntfo

Disclaimer: Contributed articles does not reflect the view of THE PH CHRONICLES. This website cannot guarantee the legitimacy of some of the information contributed to us. You may do additional research if you find some information doubtful. No part of this article maybe reproduced without permission from this website.